{
  "docId": "019dd923-5ca1-7489-b638-f79920e0da0e",
  "docSlug": "4271f4524e03d677",
  "documentTitle": "Purdue High Impact Interventions",
  "authorId": "McKinsey",
  "authorName": null,
  "documentKindSlug": "consulting-deck",
  "documentKindLabel": "Consulting deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "portrait",
  "aspectRatio": 0.773,
  "pageNumber": 8,
  "pageCount": 50,
  "prevPage": 7,
  "nextPage": 9,
  "slideType": "industry_trends",
  "function": "establish_context",
  "density": "dense",
  "nDataPoints": 20,
  "notes": "The slide uses a combination of a bar chart for historical data and a timeline for specific case examples.",
  "elementsJson": [
    "bar_chart_horizontal",
    "timeline_visual",
    "comparison_table"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5ca1-7489-b638-f79920e0da0e/8",
  "deckHref": "/decks/019dd923-5ca1-7489-b638-f79920e0da0e",
  "deckJsonHref": "/decks/019dd923-5ca1-7489-b638-f79920e0da0e.json",
  "deckAnchorHref": "/decks/019dd923-5ca1-7489-b638-f79920e0da0e#slide-8",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Recently, they are becoming a common lever for newly launched drugs and in specialty, high-value brands.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd951-cdee-73ea-b068-16f17d1b3c84",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.3,
        "x": 0.1,
        "y": 0.27
      },
      "kind": "chart",
      "text": "# of public contracts executed since 1994 globally",
      "attrs": null,
      "subkind": "bar-horizontal",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f86ef7e3-2c7f-4519-b4a0-350bf6895bf7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.5,
        "x": 0.41,
        "y": 0.27
      },
      "kind": "chart",
      "text": "Timeline of innovative contracts 2015-2017",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "36702718-8413-42d9-8288-913fd0e4d72f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "Number of public contracts: 94",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd951-cdee-73ea-b068-1902af0b6b2a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.45,
        "x": 0.1,
        "y": 0.84
      },
      "kind": "source-note",
      "text": "1 McKinsey analyzed over 200 publicly available contracts; SOURCE: 2016 ESI Drug Trend Report; Pain/inflammation spend is $52 PMPY",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9b600709-3833-44ce-87fd-99a73bc110ff",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.75,
        "x": 0.12,
        "y": 0.11
      },
      "kind": "title",
      "text": "Recently, innovative contracts are a common lever for new launches and “high-budget” brands",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "83e22c47-461f-48d0-8518-b297218b9e4e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [
    {
      "metricRaw": "Number of public contracts",
      "numberRaw": "94",
      "numberKind": "plain",
      "actionTitle": "Recently, innovative contracts are a common lever for new launches and “high-budget” brands",
      "calloutText": "Recently, they are becoming a common lever for newly launched drugs and in specialty, high-value brands.",
      "numberScale": null,
      "numberValue": 94,
      "metricFamily": "volume_count",
      "numberCurrency": null
    }
  ],
  "tools": [],
  "frameworks": [
    {
      "name": "timeline",
      "slug": null,
      "matchId": "48a7a2d4-62a1-485d-ba8e-08074908dee3",
      "evidence": "The right side of the slide presents a chronological sequence of contract examples.",
      "confidence": 1
    }
  ],
  "arcBeats": [
    {
      "to": 15,
      "from": 6,
      "beatId": "1a3ac2e9-9f33-4cb2-bee9-f10103679e84",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Problem & Complication",
      "beatSlug": "consultants-gambit-problem-complication",
      "evidence": "Barriers for execution, low number of innovative contracts",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}